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CASE REPORT
Nephrogenic systemic fibrosis (NSF) is a newly
recognized disease in patients with renal disease.1
It was initially recognized in dialysis patients with
progressive cutaneous fibrosis and was named
nephrogenic fibrosing dermopathy.2 Subsequent
reports revealed systemic involvement of other
systems such as muscular, diaphragm, pulmonary
and cardiac tissues.3,4 NSF is characterized by fi-
brosis and hardness of the skin and muscle, with
progressive limited motion and joint contraction.
The extremities, especially the legs, are the most
commonly involved areas, with the trunk being
less frequently involved.5,6 NSF is rare and affects
both genders equally over a wide range of ages
(from children to the elderly). Currently, there is
no reliable treatment for NSF. The pathogenesis
is unknown; both extrinsic and intrinsic factors
underlie overproduction of collagens and even-
tual fibrosis.7 However, no definite etiology has
been established. Recently, gadolinium (Gd)-
containing agents used in magnetic resonance
imaging (MRI) have become suspected exogenous
triggers of NSF.8 This report discusses two NSF
cases that emerged after MRI with Gd-contrast
agents. The possible roles of Gd in NSF will also
be discussed.
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Nephrogenic systemic fibrosis (NSF) is an idiopathic, progressive, systemic fibrosis that occurs in patients
with renal diseases. Recently, gadolinium-containing contrast (Gd-contrast) has become a suspected
causal factor for NFS. This report discusses two female patients with end-stage renal disease, aged 70 and
51 years, respectively, who developed histologically proven NSF after exposure to Gd-contrast. Clinically,
both patients were characterized by fibrosis and induration of skin and muscle mainly in the limbs with
joint contracture. In the first case, NSF developed gradually after undergoing evaluation by Gd-contrast
magnetic resonance imaging (MRI) and subsequent surgery for her urothelial carcinoma. In the second
patient, NSF developed after undergoing evaluation by Gd-contrast MRI for her right shoulder bursitis
with calcification, and the conditions of NSF continued to worsen after the surgical treatment of this right
shoulder lesion. Although the role of Gd-contrast in NSF is still not well known, the correlation in our
cases strongly suggests that it should be used with cautioned in patients with end-stage renal disease. Both
of our patients underwent surgery before or during the development of NSF, indicating that the surgical
procedure may be a contributing factor. [J Formos Med Assoc 2008;107(3):270–274]
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Case Reports
Case 1
A 70-year-old female had a history of poliomyelitis
with subsequent mild right lower limb weakness.
She had chronic renal insufficiency of unknown
cause for 8 years and began continuous ambula-
tory peritoneal dialysis (CAPD) in March 2000.
In September 2004, because of a gross painless
hematuria, she received cystoscopy and uretero-
scopy. Urothelial carcinoma of the bladder, right
ureter and right renal pelvis was diagnosed. She
underwent transurethral resection of the bladder
tumor and laparoscopic retroperitoneal bilateral
nephroureterectomy on September 9, 2004 soon
after the diagnosis and work-up of the cancer
stage was completed.
For cancer evaluation and postoperative 
follow-up, she received MRI with a Gd-contrast
agent (Omniscan, gadolinium diethylenetriamine
pentaacetic acid bismethylamide, GdDTPA-BMA;
1464 mg per MRI) four times in September 2004,
January 2005, October 2005, and May 2006; there
was no tumor recurrence. However, after the op-
eration, a gradual thickening and tightness of the
skin and stiffening of the muscles with restricted
joint motion in the lower limbs was noted. During
this period, she continued to receive regular CAPD
and no obvious deterioration in fluid and elec-
trolyte homeostasis was noted.
By late 2005, her knee contractions were so
severe that she could not extend her legs and a
wheelchair became necessary. She came to the neu-
rologic outpatient department for help in October
2006. Physical examination revealed marked in-
duration and brown hyperpigmentation of the
skin of the thigh and leg (Figure 1). Her leg and
thigh muscles were stiff and the range of motion
in bilateral knees was only around 30 degrees.
The trunk and upper limbs were relatively normal.
Serum electrophoresis and immune profiles, in-
cluding antinuclear antibody, rheumatoid factor,
anti-Sjögren’s syndrome A antigen, anti-Sjögren’s
syndrome B antigen, anti-Smith antigen, anti-
scleroderma antigen (SCL-70), C3 and C4 com-
plement levels, and cryoglobulin levels were all
negative. Skin and muscle biopsies from the leg
all showed fibrosis and increased numbers of
elastic fibers with increased numbers of intersti-
tial epithelioid, stellate and multinucleated cells.
Immunohistochemical studies showed some in-
terstitial cells positive for CD34, CD68 and fac-
tor XIIIa (Figure 2). She received short-term oral
prednisolone but no improvement was noted.
Case 2
A 51-year-old female had hypertension and
chronic renal insufficiency of unknown cause for
11 years. She began to receive CAPD in July 2003.
Her condition was stable until February 2006
when she suffered right shoulder pain with a grad-
ually enlarging mass in the same area. She visited
the orthopedic outpatient department. MRI with
Gd-contrast (Omniscan, GdDTPA-BMA; 1673 mg
per MRI) of the right shoulder was performed
and showed sub-deltoid bursitis with multilobed
calcification. She underwent smooth excision of
this mass on April 10, 2006. After MRI, progres-
sive pitting edema in bilateral legs appeared and
urine output decreased gradually. There was no
obvious deterioration in electrolyte homeostasis,
blood urea nitrogen or creatinine. A dialysate with
4.25% dextrose was used to increase ultrafiltra-
tion and the edema partially improved. However,
skin induration and plaques in the extremities and
lower trunk progressively developed. The patient
Figure 1. Skin changes due to nephrogenic systemic fibrosis
in Case 1. The skin of the affected leg is thickened, shiny
and hyperpigmented. Joint contraction fixed the knee at
the flexion position.
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also experienced weakness in all limbs, with pro-
gressive limitations in elbow and knee motion.
She became unable to walk in May 2006.
She was admitted to the neurology department
for suspected myopathy in July 2006. Physical ex-
amination revealed hardness and tightness in the
skin with limited range of motion in the elbows
and knees. Serum electrophoresis and autoim-
mune profiles, including anti-cyclic citrullinated
peptides, antinuclear antibodies, rheumatoid
factors, anti-Sjögren’s syndrome A antigen, anti-
Sjögren’s syndrome B antigen, anti-Smith anti-
gen, and anti-scleroderma antigen (SCL-70) were
all negative. MRI with Gd-contrast of the extrem-
ities was done in July 2006 for suspected soft 
tissue problems, which revealed nonspecific ede-
matous and inflammatory changes of the limb
muscles. However, mechanical respiratory failure
of unknown cause with CO2 retention (PaCO2 =
92.8 mmHg) and loss of consciousness occurred
1 week after MRI. She was intubated and re-
gained consciousness after mechanical ventila-
tion. Skin and muscle biopsies were performed
which showed fibrotic changes similar to those
observed in Case 1. She received oral prednisolone
for 4 weeks and one course of plasma exchange,
but no definite responses were noted. Due to no
definite etiology being found, CAPD was changed
to hemodialysis in August 2006 under the pre-
sumption that there might be unknown toxins
that had noxious effects on the muscle and skin
and which could not be removed by CAPD.
Discussion
Our two patients developed NSF after MRI with
Gd-contrast. NSF diagnosis in our uremic patients
was based on clinical skin and muscle manifesta-
tions, and characteristic histologic findings. Diag-
noses such as scleromyxedema and scleroderma
were excluded through pathologic findings in the
skin and muscle and the normal results of serum
electrophoresis.
NSF is a recently reported and serious fibros-
ing disorder that occurs in patients with renal 
insufficiency of variable duration and severity.5
Neither dialysis nor transplantation is requisite
for its development. There is also no association
with any underlying renal etiology or type of dial-
ysis.7 Clinically, cutaneous symptoms are the most
prominent (hyperpigmentation, papules and sub-
cutaneous nodules, skin thickening/hardness).
They often lead to a rugged and dimpled texture
or peau d’orange appearance. The most commonly
afflicted areas are the extremities (ankles to thighs
and wrists to arms). Truck involvement is less
frequent, and the face/neck is rarely affected.5,9
Afflicted joints usually contract, leading to a re-
stricted range of motion. Patients often become
A B
Figure 2. Histology from a skin biopsy of Case 1. (A) Diffuse fibrosis throughout the dermis and subcutaneous fat (white
arrowhead, 40×) with increased spindle fibrocytes (black arrowhead, 100×) and multinucleated cells (black arrow, 100×)
(hematoxylin & eosin). (B) Immunohistochemical study showed CD34-positive interstitial cells (CD34).
debilitated as the disease progresses.6 In some
patients, organs such as the heart, lungs, skeletal
muscles and diaphragm become involved, which
can be fatal.3
NSF histology has been documented in previ-
ous studies; it has been shown to be distinctive.2,4,10
Skin biopsies show interconnecting networks
abundant with CD34/procollagen dual-positive
spindle cells, CD68 and factor XIIIa-positive
mono- or multinucleated cells, along with thick
collagen and elastic fibers throughout the dermis
and muscles. In our patients, similar findings
were observed in skin and muscle biopsies.
The mechanism of NSF is not clear. Based on
histologic findings, it may be caused by patho-
logic relocation of circulating fibroblasts (CD34+)
to the dermis, muscles and other organs.7 Addi-
tionally, activation and infiltration of CD68+/
factor XIIIa+ dendritic cells and increased pro-
duction of transforming growth factor-β may also
be involved.4,11 However, the stimulus for these
events is not yet certain. Some studies have pro-
posed trigger factors such as dialysis fluid, drugs
such as erythropoietin, cyclosporin12 or angioten-
sin converting enzyme inhibitors,13 and recent
vascular surgery.14 However, epidemiologic stud-
ies do not show a consistent picture. Gd-contrast
agent administration, before the development of
NSF, has recently been noted. Grobner first re-
ported five patients who developed skin abnor-
malities within 2–4 weeks after Gd-enhanced
imaging; the affected patients all had metabolic
acidosis.8 He speculated that in renal failure, com-
bined metabolic acidosis and inadequate Gd-
contrast clearance could trigger the development
of NSF. Other reports have also noted Gd-contrast
exposure before the development of NSF.14–17
The odds ratio for acquiring the disease after Gd
agent exposure has been stated as 32.5.17 How-
ever, the association of metabolic acidosis with
NSF is not consistent in these series. The patho-
logic role of Gd in the development NSF is not
yet known and is presumed to involve impaired
clearance resulting in deposition of Gd in the
skin, muscles or other organs, causing tissue injury
and immunologic responses. This hypothesis is
supported by the detection of Gd within the 
tissues of patients with NSF.16,18 Due to the link
between NSF and exposure to Gd-contrast, the
US Food and Drug Administration has issued a
warning against the use of Gd-contrast in patients
with moderate-to-severe reduction in glomerular
filtration rate.
In our two cases, both developed progressive
symptoms after Gd-imaging and surgery (for uro-
logic malignancy and right shoulder mass). In
addition, Case 2 had acute deterioration including
limb edema or weakness of respiratory muscle
with CO2 retention after each administration of
Gd-contrast for MRI. These associations strongly
suggest a causal relationship between Gd and
NSF. Interestingly, our patients both received sur-
gery before or during the development of NSF.
This might suggest surgery as a contributing fac-
tor for NSF.14 Some studies indicate that inflam-
matory events such as major surgery, infection or
vascular events play a role in NSF.19
In summary, Gd-contrast should only be used
with caution in patients with end-stage renal 
disease, especially in those who have recently 
undergone or will undergo surgery.
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